BTI
REGN icon

Blue Trust Inc’s Regeneron Pharmaceuticals REGN Stock Holding History

Blue Trust Inc’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$536K Buy
859
+87
+11% +$59.2K 0.01% 459
2026
Q1 		$596K Buy
772
+533
+223% +$408K 0.01% 434
2025
Q4 		$184K Sell
239
-40
-14% -$27.2K ﹤0.01% 810
2025
Q3 		$157K Buy
279
+51
+22% +$28.8K ﹤0.01% 894
2025
Q2 		$120K Sell
228
-103
-31% -$57.5K ﹤0.01% 975
2025
Q1 		$210K Buy
331
+51
+18% +$35.1K ﹤0.01% 689
2024
Q4 		$199K Sell
280
-238
-46% -$200K ﹤0.01% 662
2024
Q3 		$544K Buy
518
+235
+83% +$262K 0.01% 432
2024
Q2 		$272K Buy
283
+215
+316% +$208K ﹤0.01% 590
2024
Q1 		$65.4K Sell
68
-74
-52% -$70.4K ﹤0.01% 834
2023
Q4 		$116K Buy
142
+66
+87% +$54.4K ﹤0.01% 625
2023
Q3 		$55K Buy
76
+12
+19% +$9.43K ﹤0.01% 817
2023
Q2 		$53K Sell
64
-174
-73% -$134K ﹤0.01% 678
2023
Q1 		$172K Buy
238
+40
+20% +$30.2K ﹤0.01% 590
2022
Q4 		$137K Buy
198
+149
+304% +$110K ﹤0.01% 568
2022
Q3 		$29K Buy
49
+30
+158% +$18.9K ﹤0.01% 942
2022
Q2 		$13K Buy
+19
New +$12.3K ﹤0.01% 1118

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Blue Trust Inc's REGN Position: Q2 2026 in Review

Blue Trust Inc increased its Regeneron Pharmaceuticals (REGN) stake by 11% in Q2 2026, buying an estimated $59.2K and bringing the position to 859 shares worth $536K. The position accounts for 0.01% of the portfolio, ranked #459.

Blue Trust Inc first reported a position in REGN in Q2 2022 and has held it in 17 quarters since. The position peaked at $596K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Blue Trust Inc held 859 shares of Regeneron Pharmaceuticals worth $536K as of Q2 2026.
  • Blue Trust Inc bought 87 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $59.2K.
  • Regeneron Pharmaceuticals made up 0.01% of Blue Trust Inc's portfolio in Q2 2026, its #459 holding.
  • Blue Trust Inc first reported a position in Regeneron Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • Blue Trust Inc's Regeneron Pharmaceuticals position peaked at $596K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.